Emgality คือยาใหม่ในการรักษาไมเกรน มีที่ใช้ใน

  • ป้องกันไมเกรนเรื้อรัง  ไมเกรนเรื้อรังคือไมเกรนที่มีอาการเกิน 15วันต่อเดือน ต่างจากไมเกรนปกติ
  • รักษาปวดศีรษะแบบคลัสเตอร์ (cluster headache) อาการของคลัสเตอร์ ต่างจากปวดหัวทั่วไปคือปวดรุนแรงในช่วงเวลาหนึ่ง ติดๆกัน1 สัปดาห์จนถึงปี และแยกโดยมีช่วงหายปวดหัวเลยอย่างน้อย 3 เดือน

Emgality มีสารออกฤทธิ์คือ galcanezumab เป็น monoclonal antibody ต่อ c-GMP

Emgality is a proprietary prescription drug approved by the FDA for use by adults in the following cases:

Prevents chronic and episodic migraines. According to the International Headache Society, people with chronic migraine have 15 or more migraine days per month. People with episodic migraine have less than 15 days of migraine per month.
Treats headaches with episodic outbreaks. According to the International Headache Society, people with episodic cluster headaches have headaches in groups (close in time to each other). Groups last from 1 week to 1 year. They are separated by at least 3 months of a painless period.
Emgality comes in the form of a pre-filled pen or syringe that you will use for your monthly injection.

Emgality contains the drug galcanezumab, which is a monoclonal antibody. A monoclonal antibody is a biological preparation developed from cells of the immune system in the laboratory. It blocks the activity of certain proteins in the body.

FDA approval
Emgality was first approved by the Food and Drug Administration (FDA) in September 2018.

Drug of A new Kind
Emgality belongs to a new class of drugs called calcitonin gene-related peptide antagonists (CGRP). CGRP antagonists have been specifically developed to prevent migraines. While Emgality is approved for the treatment of cluster headaches and migraine prevention, other CGRP antagonists are approved only for migraine prevention.

Emgality became the third drug of this class approved by the Food and Drug Administration (FDA). Other FDA-approved CGRP antagonists are Aimovig, approved in May 2018, Ajovy, approved in September 2018, and Vyepti, approved in February 2020.

In clinical studies, Emgality has been found to be effective in preventing chronic and episodic migraines and treating episodic cluster headaches.

Emgality may be a particularly effective option for people who have not been able to sufficiently reduce the number of cluster headaches or migraine days with other treatments. It may also be a good option for people who cannot take other medications to prevent migraines or treat cluster headaches due to drug

Related Entries